NCT06936527

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

An Open-label, Multicenter Phase Ib/II Clinical Study: Aim to Valuate the Efficacy and Safety of XS-03 Comination With FOLFOX or FOLFIRI and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

• Status: Enrolling By Invitation
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 102 (estimated)
• Sponsor: NovaOnco Therapeutics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation

Conditions

• Colorectal Cancer
• Metastatic Colorectal Cancer With RAS Mutation

Interventions

Type	Name	Description
BIOLOGICAL	Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI	XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
BIOLOGICAL	Drug: XS-03	XS-03 orally
BIOLOGICAL	Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI	Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

Timeline

• Start date: 2025-05-23
• Primary completion: 2028-04-30
• Completion: 2028-07-30
• First posted: 2025-04-20
• Last updated: 2025-09-03

Locations

1 site across 1 country: China